Skip to ContentSkip to Navigation
Practical matters How to find us dr. T. van Meerten

Publications

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma

DSP107 combines inhibition of CD47/SIRPĪ± axis with activation of 4-1BB to trigger anticancer immunity

Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma

Outcome of COVID-19 in Patients With Mantle Cell Lymphoma-Report From the European MCL Registry

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis

CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties

Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma

Read more

Press/media

Axi-cel CAR-T significantly improves EFS among older patients with non-Hodgkin lymphoma

Dit was 2021: Genezen

UMCG gaat zelf medicijn tegen lymfeklierkanker maken

Podcast De Genezers over CAR T-celtherapie

Gronings ziekenhuis gaat prijzig kankermedicijn zelf maken met miljoenensubsidie

€ 30 miljoen subsidie voor UMCG-onderzoek naar veelbelovende kankerbehandeling

Wanneer milieuwetgeving de strijd tegen kanker hindert

Doorbraak in behandeling lymfeklierkanker

Read more